Why was DRDO’s COVID-19 drug licence given to only one laboratory, asks Madras HC
The Hindu
The Court asked why licenses had not been issued to as many reputed laboratories as possible, to ramp up production of the oral powder that has been approved to be used as an adjunct in treating COVID-19 patients
The Madras High Court on Thursday directed the Centre to explain by Friday the reason for the Defence Research and Development Organisation (DRDO) having partnered with Dr. Reddy’s Laboratory in Hyderabad alone to produce 2-deoxy-D-glucose (2-DG), an adjunct drug to treat COVID-19 patients. Justices N. Kirubakaran and T.V. Thamilselvi wanted to know why the DRDO had not issued licences to as many reputed laboratories as possible to ramp up production of the oral powder that has been approved to be used as an adjunct in treating moderate to severe COVID-19 patients.More Related News